The rise in geriatric population and their vulnerability towards various chronic diseases are boosting the global sedation in ICU setting market, predicts Fortune Business Insights in their new study. The study is titled, “Sedation in ICU settings market: Global Market Analysis, Insights, and Forecasts 2019-2026”. The report predicts the market to witness promising growth during the forecast period on account of the rising number of patient pool with serious medical conditions.
Detailed Table of Content:
- Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1. Guidelines for Sedation in ICU Setting – for Key Countries
4.2. Technological Advancements
4.3. Pipeline Analysis
4.4. Advantages & Disadvantages of Various Types of Sedation in ICU Setting by Drug Class.
- Global Sedation in ICU Setting Market Analysis, Insights, and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug/Drug Class
5.2.1. Propofol
5.2.2. Benzodiazepams (Midazolam, etc.)
5.2.3. Dexmedetomidine
5.2.4. Remifentanil
5.2.5. Others
5.3. Market Analysis, Insights, and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Rest of World
- North America Sedation in ICU Setting Market Analysis, Insights, and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis, Insights, and Forecast – By Drug/Drug Class
6.2.1. Propofol
6.2.2. Benzodiazepams (Midazolam, etc.)
6.2.3. Dexmedetomidine
6.2.4. Remifentanil
6.2.5. Others
6.3. Market Analysis, Insights, and Forecast – By Country
6.3.1. U.S.
6.3.2. Canada
- Europe Sedation in ICU Setting Market Analysis, Insights, and Forecast, 2015-2026
7.1. Key Findings / Summary
7.2. Market Analysis, Insights, and Forecast – By Drug/Drug Class
7.2.1. Propofol
7.2.2. Benzodiazepams (Midazolam, etc.)
7.2.3. Dexmedetomidine
7.2.4. Remifentanil
7.2.5. Others
7.3. Market Analysis, Insights, and Forecast – By Country/Sub-region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Sweden
7.3.7. Norway
7.3.8. Denmark
7.3.9. Finland
7.3.10. Benelux
7.3.11. Russia
7.3.12. Rest of Europe
- Asia Pacific Sedation in ICU Setting Market Analysis, Insights and Forecast, 2015-2026
8.1. Key Findings / Summary
8.2. Market Analysis, Insights, and Forecast – By Drug/Drug Class
8.2.1. Propofol
8.2.2. Benzodiazepams (Midazolam, etc.)
8.2.3. Dexmedetomidine
8.2.4. Remifentanil
8.2.5. Others
8.3. Market Analysis, Insights, and Forecast – By Country/Sub-region
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. South Korea
8.3.5. Rest of Asia Pacific
- Rest of World Sedation in ICU Setting Market Analysis, Insights and Forecast, 2015-2026
9.1. Key Findings / Summary
9.2. Market Analysis, Insights, and Forecast – By Drug/Drug Class
9.2.1. Propofol
9.2.2. Benzodiazepams (Midazolam, etc.)
9.2.3. Dexmedetomidine
9.2.4. Remifentanil
9.2.5. Others
Continued...
Neurodegenerative Diseases Drugs Market
